Company Overview of Aspireo Pharmaceuticals Ltd.
Aspireo Pharmaceuticals Ltd. develops compounds for the treatment of acromegaly and certain hormone active tumor types resulting from hypophyse disorders. It offers Somatoprim (DG3173), a novel somatostatin analogue that regulates endocrine system and affects neurotransmission and cell proliferation via interaction with G-protein-coupled somatostatin receptors and inhibition of the release of various secondary hormones. The company provides Somatoprim to treat patients with the various indications, including acromegaly, carcinoid tumors, GEP-NET, diabetic retinopathy, and cushings diseases. Aspireo Pharmaceuticals Ltd. is based in Tel Aviv, Israel.
Key Executives for Aspireo Pharmaceuticals Ltd.
Aspireo Pharmaceuticals Ltd. Key Developments
Similar Private Companies By Industry
|Accelerated Evolution Biotechnologies Ltd||Middle East/Africa|
|High Tech Lipids Ltd.||Middle East/Africa|
|BioCep Ltd.||Middle East/Africa|
|Thrombotech Technologies Ltd.||Middle East/Africa|
|Optitest Ltd.||Middle East/Africa|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- Boston, MA | PwCPosted: Aug 28
- Adelphi, MD | University of Maryland University CollegePosted: May 07
- Efland, NC | Orange County SchoolsPosted: May 19
- San Francisco, CA | Confidential Biotechnology CompanyPosted: May 13
Sponsored Financial Commentaries
To contact Aspireo Pharmaceuticals Ltd., please visit www.aspireopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.